Haley M. Beckmann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Haley M. Beckmann has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Brandon Matthew Meyers
Juravinski Cancer Centre, Hamilton, ON L8V 5C2, Canada
5 shared publications - Chris J. O'Callaghan
Queen’s University 22 Canadian Cancer Trials Group Kingston, Canada
5 shared publications - Christina A. Kim
CancerCare Manitoba, Winnipeg, MB R2H 2A6, Canada
5 shared publications - Daniel John Renouf
Pancreas Centre BC, Vancouver, Canada
5 shared publications - David F. Schaeffer
University of British Columbia 1 Department of Pathology and Laboratory Medicine Vancouver, Canada
5 shared publications - Derek J. Jonker
Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada
5 shared publications
Latest Publications
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Supplementary Table S2 from Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Supplementary Table S2 from Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Supplementary Table S1 from Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Supplementary Table S1 from Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (16) , OF1-OF9
Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Purpose: Pre-existing and emerging molecular targeted therapies have been identified for the treatment of pancreatic ductal adenocarcinoma (PDAC) and exemplify the need for incorporating tumor sequencing into routine clinical practice. Tumor profiling through circulating tumor DNA (ctDNA) represents an important opportunity in PDAC because of the aggressive nature of the disease. Circulating tumor fraction (CTF) levels are highly variable within and between cancer types and influence the accuracy of plasma-based tumor profiling, and the variability and factors related to CTF levels in PDAC are not well understood. Experimental Design: ctDNA sequencing (PredicineATLAS) and clinical metadata from a cohort of 166 patients with metastatic PDAC (mPDAC) were generated as part of the PA.7 trial (NCT02879318). Patients were stratified into high CTF (>30% CTF; 35/166, 21.08%) and low CTF (131/166, 78.92%) groups for comparative analysis. Matched RNA sequencing data were available for 20 patients. Results: High CTF was associated with lower overall survival (hazard ratio = 1.87; 95% confidence interval, 1.27–2.75; P = 0.0014) as well as clinical presentation that was indicative of higher disease burden, with CTF highest in patients that had liver metastases and distant metastases including bulky lymph nodes versus patients with no liver metastases (P < 0.001). Exploratory gene expression analysis revealed a positive association between CTF and upregulation of cell cycle–related pathways, which included those involving CDK4 (P = 0.0093) and MT2A (P = 0.012), as well as glycolytic (P = 0.0028) and basal-like (P = 0.029) subtyping genes. Conclusions: These data demonstrate the heterogeneity of CTF and its associated factors in mPDAC, which converge toward an aggressive phenotype from both clinical and molecular standpoints.
- 18 June 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (16) , OF1-OF9
Open AccessClinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Purpose: Pre-existing and emerging molecular targeted therapies have been identified for the treatment of pancreatic ductal adenocarcinoma (PDAC) and exemplify the need for incorporating tumor sequencing into routine clinical practice. Tumor profiling through circulating tumor DNA (ctDNA) represents an important opportunity in PDAC because of the aggressive nature of the disease. Circulating tumor fraction (CTF) levels are highly variable within and between cancer types and influence the accuracy of plasma-based tumor profiling, and the variability and factors related to CTF levels in PDAC are not well understood. Experimental Design: ctDNA sequencing (PredicineATLAS) and clinical metadata from a cohort of 166 patients with metastatic PDAC (mPDAC) were generated as part of the PA.7 trial (NCT02879318). Patients were stratified into high CTF (>30% CTF; 35/166, 21.08%) and low CTF (131/166, 78.92%) groups for comparative analysis. Matched RNA sequencing data were available for 20 patients. Results: High CTF was associated with lower overall survival (hazard ratio = 1.87; 95% confidence interval, 1.27–2.75; P = 0.0014) as well as clinical presentation that was indicative of higher disease burden, with CTF highest in patients that had liver metastases and distant metastases including bulky lymph nodes versus patients with no liver metastases (P < 0.001). Exploratory gene expression analysis revealed a positive association between CTF and upregulation of cell cycle–related pathways, which included those involving CDK4 (P = 0.0093) and MT2A (P = 0.012), as well as glycolytic (P = 0.0028) and basal-like (P = 0.029) subtyping genes. Conclusions: These data demonstrate the heterogeneity of CTF and its associated factors in mPDAC, which converge toward an aggressive phenotype from both clinical and molecular standpoints.
- Open Access
Deep learning inference of universal dormancy pseudotime reveals the cellular targets of anti-cancer therapies
Controlled exit from and re-entry into the cell cycle is essential for multi-cellular life, while aberrant quiescent and senescent cell states have been implicated in age-related diseases and cancer treatment evasion. Recent molecular and imaging studies suggest non-cycling cellular states exist along a continuum of deepening dormancy, whereby the probability of cell cycle re-entry decreases with distance from the restriction point. We trained a probabilistic deep-learning model that enables mapping of heterogeneous single cell transcriptomic datasets into an interpretable latent space that encodes a common “dormancy pseudotime”. We demonstrate that our model enables robust inference of active cell cycle states, and validate in diverse biological contexts that the inferred location along dormancy pseudotime represents a continuum from quiescence to durably arrested states. Applying dormancy pseudotime inference to pre- and post-treatment time points from patients undergoing anti-cancer treatment, we uncover new insights into the distinct tumour cell dormancy states targeted by immune checkpoint inhibitors and platinum-taxane chemotherapy. Given the ubiquity of single cell transcriptomics, we anticipate that dormancy pseudotime analysis will be widely applied to shed new light on the complex interplay between cycling and non-cycling cellular states in health and disease.
Open AccessDeep learning inference of universal dormancy pseudotime reveals the cellular targets of anti-cancer therapies
Controlled exit from and re-entry into the cell cycle is essential for multi-cellular life, while aberrant quiescent and senescent cell states have been implicated in age-related diseases and cancer treatment evasion. Recent molecular and imaging studies suggest non-cycling cellular states exist along a continuum of deepening dormancy, whereby the probability of cell cycle re-entry decreases with distance from the restriction point. We trained a probabilistic deep-learning model that enables mapping of heterogeneous single cell transcriptomic datasets into an interpretable latent space that encodes a common “dormancy pseudotime”. We demonstrate that our model enables robust inference of active cell cycle states, and validate in diverse biological contexts that the inferred location along dormancy pseudotime represents a continuum from quiescence to durably arrested states. Applying dormancy pseudotime inference to pre- and post-treatment time points from patients undergoing anti-cancer treatment, we uncover new insights into the distinct tumour cell dormancy states targeted by immune checkpoint inhibitors and platinum-taxane chemotherapy. Given the ubiquity of single cell transcriptomics, we anticipate that dormancy pseudotime analysis will be widely applied to shed new light on the complex interplay between cycling and non-cycling cellular states in health and disease.
- 1 January 2025
- Published by Royal Society of Chemistry (RSC) in Lab on a Chip
- Vol. 25 (19) , 4972-4985
High-speed cell partitioning through reactive machine learning-guided inkjet printing
We present a high-throughput single cell dispensing instrument using an inkjet printhead under real-time optical monitoring, guided by machine learning feedback. The instrument rapidly partitions cells for assays such as in whole genome sequencing.
- 1 January 2025
- Published by Royal Society of Chemistry (RSC) in Lab on a Chip
- Vol. 25 (19) , 4972-4985
High-speed cell partitioning through reactive machine learning-guided inkjet printing
We present a high-throughput single cell dispensing instrument using an inkjet printhead under real-time optical monitoring, guided by machine learning feedback. The instrument rapidly partitions cells for assays such as in whole genome sequencing.